论文部分内容阅读
为了前瞻性地评估多酶抑制剂的使用顺序,对比索拉菲尼-舒尼替尼(So-Su)与舒尼替尼-索拉菲尼(Su-So)两种治疗方案对转移性肾细胞癌患者的疗效,在未接受全身性治疗的转移性肾细胞癌患者中进行了一项多中心、随机、开放性的三期临床研究,并依据Memorial Sloan Kettering肿瘤中心的风险评分对患者进行分层(有利的或者居中的)。患者被随机分为索拉菲尼400 mg 2次/d-舒尼替尼50 mg 1次/d与舒尼替尼400 mg 2次/d-索拉菲尼50 mg 1次/d两组。
To prospectively evaluate the order of use of multiple enzyme inhibitors, we compared the effects of two treatment regimens, So-Su and Sunitinib (Su-So) on metastatic In a multicenter, randomized, open-label, phase III clinical trial of metastatic renal cell carcinoma without systemic therapy in patients with renal cell carcinoma, the patients were evaluated according to the Memorial Sloan Kettering Cancer Center risk score Layered (favored or centered). Patients were randomized to either sorafenib 400 mg twice / d-sunitinib 50 mg once daily versus sunitinib 400 mg twice daily or sorafenib 50 mg once daily .